Drug treatment of hypertension in pregnancy

Drugs

Volumn 74, Issue 3, 2014, Pages 283-296

  Brown, Catherine M ^a   Garovic, Vesna D ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CLONIDINE; DIAZEPAM; DIAZOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FISH OIL; GASOTRANSMITTER; HEME OXYGENASE 1; HYDRALAZINE; LABETALOL; MAGNESIUM SULFATE; MARINOBUFAGENIN; METHYLDOPA; NIFEDIPINE; NIMODIPINE; NITRATE; NITROPRUSSIDE SODIUM; POLY(ADENOSINE DIPHOSPHATE RIBOSE); THIAZIDE DIURETIC AGENT; URAPIDIL; VASODILATOR AGENT; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; DRUG THERAPY; HUMAN; MATERNAL HYPERTENSION; NONHUMAN; PODOCYTE; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; REVIEW; BLOOD PRESSURE MEASUREMENT; CLASSIFICATION; FEMALE; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; PRACTICE GUIDELINES AS TOPIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; VASODILATOR AGENTS;

EID: 84895805088     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0187-7     Document Type: Review

References (68)

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1-22.
2. Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens. 2008;26(2):295-302. doi: 10.1097/HJH.0b013e3282f1a953.
3. Pettit F, Brown MA. The management of pre-eclampsia: what we think we know. Eur J Obstet Gynecol Reprod Biol. 2012;160(1):6-12. doi: 10.1016/j.ejogrb.2011.09.049.
4. Trogstad L, Magnus P, Stoltenberg C. Pre-eclampsia: risk factors and causal models. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):329-42.
5. James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol. 2010;221(4):363-78. doi: 10.1002/path.2719.
6. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology. 2009;24:147-58. doi: 10.1152/physiol.00043.2008.
7. Hertig A, Liere P. New markers in preeclampsia. Clin Chim Acta. 2010;411(21-22):1591-5. doi: 10.1016/j.cca.2010.07.020.
8. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-44. doi: 10.1016/S0140-6736(10)60279-6.
9. Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta. 2011;32(Suppl):S4-16. doi: 10.1016/j.placenta.2010.11.022.
10. Brown CM, Garovic VD. Mechanisms and management of hypertension in pregnant women. Curr Hypertens Rep. 2011;13:338-46. doi: 10.1007/s11906-011- 0214-y.
11. Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand. 1995;74(10):772-6.
12. Smith G, Pell J, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet. 2001;357(9273):2002-6. doi: 10.1016/s0140-6736(00)05112-6.
13. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ. 2003;326(7394):845. doi: 10.1136/bmj.326.7394.845.
14. ACOG. Practice bulletin #33: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99(1):159-67.
15. ACOG Practice Bulletin. Chronic hypertension in pregnancy. ACOG Committee on Practice Bulletins. Obstet Gynecol. 2001;98(1 suppl):177-85.
16. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-31. doi: 10.1097/01.AOG.0000437382.03963.88.
17. Anderson GD, Carr DB. Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clin Pharmacokinet. 2009;48(3):159-68. doi: 10.2165/00003088-200948030-00002.
18. Magee LA. Drugs in pregnancy. Antihypertensives. Best Pract Res Clin Obstet Gynaecol. 2001;15(6):827-45. doi: 10.1053/beog.2001.0232.
19. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51(4):960-9. doi: 10.1161/HYPERTENSIONAHA.106. 075895.
20. James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart. 2004;90(12):1499-504. doi: 10.1136/hrt.2004.035444.
21. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647-9.
22. Khalil A, Harrington K, Muttukrishna S, Jauniaux E. Effect of antihypertensive therapy with alpha-methyldopa on uterine artery Doppler in pregnancies with hypertensive disorders. Ultrasound Obstet Gynecol. 2010;35(6):688-94. doi: 10.1002/uog.7611.
23. Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf. 2001;24(6):457-74.
24. Rothberger S, Carr D, Brateng D, Hebert M, Easterling TR. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am J Hypertens. 2010;23(11):1234-40. doi: 10.1038/ajh.2010.159.
25. Horvath JS, Phippard A, Korda A, Henderson-Smart DJ, Child A, Tiller DJ. Clonidine hydrochloride - a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol. 1985;66(5):634-8.
26. Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol. 2011;31(1):70-85. doi: 10.1016/j.semnephrol.2010.10.007.
27. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301(6752):587-9.
28. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955-60. doi: 10.1136/bmj.327.7421.955.
29. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007(1):CD002252. doi: 10.1002/14651858.CD002252.pub2.
30. Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahon LP, et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol. 2009;49(3):242-6. doi: 10.1111/j.1479-828X.2009.01003.x.
31. Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Hypertension Guideline Committee, Society of Obstetricians and Gynaecologists of Canada. Treatment of the hypertensive disorders of pregnancy. In: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl 1):S24-36.
32. Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol. 1996;174(3):823-8.
33. Papatsonis DN, Lok CA, Bos JM, Geijn HP, Dekker GA. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001;97(2):122-40.
34. Widerlov E, Karlman I, Storsater J. Hydralazine-induced neonatal thrombocytopenia. N Engl J Med. 1980;303(21):1235.
35. Shoemaker CT, Meyers M. Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity. Am J Obstet Gynecol. 1984;149(2):171-3.
36. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984;150(7):831-5.
37. Jim B, Sharma S, Kebede T, Acharya A. Hypertension in pregnancy: a comprehensive update. Cardiol Rev. 2010;18(4):178-89. doi: 10.1097/CRD. 0b013e3181c60ca6.
38. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-51. doi: 10.1056/NEJMoa055202.
39. Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K, Mogun H, Ecker JL, et al. Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension. 2012;60(4):913-20. doi: 10.1161/HYPERTENSIONAHA.112.197095.
40. Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2010;11:CD000025. doi: 10.1002/14651858.CD000025.pub2.
41. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007(2):CD004659. doi: 10.1002/14651858.CD004659.pub2.
42. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.
43. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: NICE 2010. Report No.: CG107.
44. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402-14. doi: 10.1097/AOG.0b013e3181e9322a.
45. Bujold E. Prevention of pre-eclampsia with low-dose aspirin. J Postgrad Med. 2011;57(2):89-90. doi: 10.4103/0022-3859.81857.
46. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med. 2010;362(14):1282-91. doi: 10.1056/NEJMoa0908056.
47. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2010(8):CD001059. doi: 10.1002/14651858.CD001059. pub3.
48. European Society of Gynecology, Association for European Paediatric C, German Society for Gender Medicine, Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147-97. doi: 10.1093/eurheartj/ehr218.
49. Olsen SF, Osterdal ML, Salvig JD, Weber T, Tabor A, Secher NJ. Duration of pregnancy in relation to fish oil supplementation and habitual fish intake: a randomised clinical trial with fish oil. Eur J Clin Nutr. 2007;61(8):976-85. doi: 10.1038/sj.ejcn.1602609.
50. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130-7. doi: 10.1053/j.semperi.2009.02.010.
51. Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M et al. The control of hypertension in pregnancy study pilot trial. BJOG. 2007;114(6):770, e13-20. doi: 10.1111/j.1471-0528.2007.01315.x.
52. Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, et al. Dysregulation of hydrogen sulfide producing enzyme cystathionine gamma-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. Circulation. 2013;127(25):2514-22. doi: 10.1161/CIRCULATIONAHA. 113.001631.
53. Mizutani S, Wright JW, Kobayashi H. Placental leucine aminopeptidase- and aminopeptidase A-deficient mice offer insight concerning the mechanisms underlying preterm labor and preeclampsia. J Biomed Biotechnol. 2011;2011:286947. doi: 10.1155/2011/286947.
54. George EM, Cockrell K, Aranay M, Csongradi E, Stec DE, Granger JP. Induction of heme oxygenase 1 attenuates placental ischemia-induced hypertension. Hypertension. 2011;57:941-8. doi: 10.1161/hypertensionaha.111. 169755.
55. Uddin MN, Horvat D, DeMorrow S, Agunanne E, Puschett JB. Marinobufagenin is an upstream modulator of Gadd45a stress signaling in preeclampsia. Biochim Biophys Acta. 2011;1812(1):49-58. doi: 10.1016/j.bbadis.2010.09.006.
56. McGuane J, Conrad K. GPCRs as potential therapeutic targets in preeclampsia. Drug Discov Today Dis Models. 2012;9(3):e119-27. doi: 10.1016/j.ddmod.2012.05.001.
57. Walsh SK, English FA, Crocker IP, Johns EJ, Kenny LC. Contribution of PARP to endothelial dysfunction and hypertension in a rat model of pre-eclampsia. Br J Pharmacol. 2012;166(7):2109-16. doi: 10.1111/j.1476-5381. 2012.01906.x.
58. Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide. 2000;4(4):441-58. doi: 10.1006/niox.2000.0296.
59. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov. 2010;9(9):728-43. doi: 10.1038/nrd3228.
60. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049-51. doi: 10.1016/S0140-6736(04)16456-8.
61. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50. doi: 10.1016/j.jash.2010.02. 005.
62. Martin JN Jr, Thigpen BD, Moore RC, Rose CH, Cushman J, May W. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol. 2005;105(2):246-54. doi: 10.1097/01.AOG.0000151116. 84113.56.
63. August P. Preeclampsia: new thoughts on an ancient problem. J Clin Hypertens. 2000;2(2):115-23.
64. Antenatal Care. Routine care for the healthy pregnant woman. London: National Institute for Health and Clinical Excellence: Guidance; 2008.
65. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731-68. doi: 10.1097/HJH.0b013e328363e964.
66. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87. doi: 10.1097/HJH.0b013e3281fc975a.
67. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;7:CD001449. doi: 10.1002/14651858.CD001449.pub3.
68. Moser M, Brown CM, Rose CH, Garovic VD. Hypertension in pregnancy: is it time for a new approach to treatment? J Hypertens. 2012;30(6):1092-100. doi: 10.1097/HJH.0b013e3283536319